Attal-Khémis S, Dalmeyda V, Morfin R. Change of 7alpha-hydroxy-dehydroepiandrosterone levels in serum of mice treated by cytochrome P450-modifying agents.
Life Sci 1998;
63:1543-53. [PMID:
9808065 DOI:
10.1016/s0024-3205(98)00421-4]
[Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Dehydroepiandrosterone (DHEA) is 7alpha-hydroxylated in liver, brain and other organs of murine and in other species. Several works suggest that the 7alpha-hydroxy-DHEA produced may be one of the native antiglucocorticoids, and compounds modifying its production may prove useful in investigation of 7alpha-hydroxy-DHEA production and effects. After treatment of mice with dexamethasone, phenobarbital, trilostane, melatonin or metyrapone, we have used gas chromatography-mass spectrometry with negative ion detection for measurement of 7alpha-hydroxy-DHEA levels in serum of control and treated animals. The 7alpha-hydroxylating rates of liver and brain microsomes from the same animals were also measured. Results showed that serum levels of 7alpha-hydroxy-DHEA were significantly increased after treatment by all compounds except metyrapone. Significantly increased 7alpha-hydroxy-DHEA levels were directly related with significantly increased 7alpha-hydroxylation yields in liver and not in brain. In contrast, metyrapone decreased 7alpha-hydroxylation in liver and brain. These findings indicate that in brain and in liver, different enzyme systems may be responsible for production of 7alpha-hydroxy-DHEA and that treatment-induced modifications of circulating 7alpha-hydroxy-DHEA levels are mainly due to change of 7alpha-hydroxylating rates in liver.
Collapse